 |
|
|
| |
Efficacy and safety of using bictegravir / emtricitabine / tenofovir alafenamide
(BIC/FTC/TAF) in a test and treat model: the FAST Study
|
| |
| |
EACS 2021 Oct 27-30
A. Bachelard1, V. Isernia1, C. Charpentier2,3, A. Benalycherif4, Z. Julia1, S. Le Gac1, R. Landman1,2,4, D. Descamps2,3, G. Peytavin5,2, L. Assoumou4, J. Ghosn1,2
1Hospital Bichat - Claude-Bernard, Infectious and Tropical Diseases, Paris, France, 2Universite de Paris, IAME - UMR 1137 INSERM, Paris, France, 3Hospital Bichat - Claude-Bernard, Virology Laboratory, Paris, France, 4Hospital Bichat-Claude Bernard, IMEA, Paris, France, 5Hospital Bichat - Claude-Bernard, Pharmacology-Toxicology Laboratory, Paris, France
Conclusion
These results suggest that BIC/FTC/TAF is safe and effective for same-day ART initiation in a test-and-treat setting. Follow-up will continue until W48.
|
| |
|
|
|
|
|
